MPM Oncology Impact Management »

Xeris Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Xeris Pharmaceuticals (XERS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Xeris Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Xeris Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xeris Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $7.4M 4.0M 1.86
2023-06-30 $10M 4.0M 2.62

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Olema Pharmaceuticals Common (OLMA)
Geron Corporation Common (GERN)
Repare Therapeutics Common (RPTX)
iTeos Therapeutics Common (ITOS)
Intellia Therapeutics Common (NTLA)
Moonlake Immunotherapeutics Common (MLTX)
Iovance Biotherapeutics Common (IOVA)
Crinetics Pharmaceuticals Common (CRNX)
Insmed Incorporated Common (INSM)
Structure Therapeutics Common (GPCR)
Verve Therapeutics Common (VERV)
Relay Therapeutics Common (RLAY)
Regenxbio Common (RGNX)
Cymabay Therapeutics Common

View all positions for MPM Oncology Impact Management

Top funds holding Xeris Pharmaceuticals

Vanguard Group
Rosalind Advisors
Millennium Management
D. E. Shaw & Co
Redmile Group
Citadel Advisors
Invenomic Capital Management
Tudor Investment Corporation
Lazard Asset Management
Charles Schwab Investment Management
Bank of New York Mellon
Jpmorgan Chase & Co
Rubric Capital Management
Barclays
AQR Capital Management

View all funds holding Xeris Pharmaceuticals